文献速递白血病

慢性髓性白血病:耐药与持续存在的概念及其与BCR-ABL1转录本类型的关系

Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type.
PubMed 文献 · Leukemia · 2019-08-27

该综述探讨慢性髓性白血病中TKI耐药(不超过10%患者)与微小残留病持续存在(绝大多数患者)的区别,提出M-bcr断点位置导致e13a2和e14a2两种转录本,后者可能因编码相差25个氨基酸的p210BCR-ABL1蛋白而影响持续存在,并关联更深的分子学反应和无治疗缓解。

要点

  • TKI耐药少见(不超过10%),是死亡原因;持续存在常见,可正常生活但可能需终身治疗。
  • 耐药与持续存在原因异质且可能不同,耐药需不同治疗。
  • e14a2转录本与更多更深分子学反应及更高无治疗缓解概率相关。

核心结论

  • 耐药是少数患者死亡原因,持续存在是多数患者需终身治疗但生活质量正常的状态。
  • BCR基因外显子14是否包含于mRNA(e13a2 vs e14a2)导致p210BCR-ABL1蛋白相差25个氨基酸,可能是持续存在的原因。
  • e14a2转录本与更多更深分子学反应及更高无治疗缓解概率相关。

研究设计与样本

  • 本文为对BCR-ABL1转录本类型与TKI反应、治疗结局及免疫反应关系的批判性综述。

主要发现

  • TKI耐药发生于不超过10%的患者,持续存在发生于绝大多数患者。
  • e14a2转录本与更多更深分子学反应及更高无治疗缓解概率相关。

关键数值与推荐

  • TKI耐药发生率不超过10%。
  • e13a2和e14a2两种mRNA分别对应包含或不包含BCR外显子14。
  • e13a2和e14a2编码的p210BCR-ABL1蛋白相差25个氨基酸。

临床怎么用

  • 区分耐药与持续存在的不同机制,耐药需异质性治疗。
  • 关注BCR-ABL1转录本类型(e13a2 vs e14a2)对TKI反应和无治疗缓解概率的潜在影响。

局限性

  • 持续存在原因可能与耐药不同,本文提出的转录本类型假说基于批判性综述,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic myeloid leukemia is driven by a hybrid gene, BCR-ABL1, that codes for a leukemogenic tyrosine kinase (TK) protein of 210 KDa (p210BCR-ABL1). Resistance to TK inhibitor (TKI) therapy occurs in relatively few patients, no more than 10%, while persistence of minimal residual disease during TKI therapy occurs in the great majority of patients. Resistance is a cause of death, persistence is compatible with a fairly normal length and quality of life, but may require lifelong treatment. The causes of resistance are heterogeneous, including the development of other genomic abnormalities or the altered expression of other genes, requiring different treatments. The causes of persistence may not be the same as those of resistance. We hypothesize that the variability in breakpoint position within the Major-breakpoint cluster region (M-bcr), resulting in two different messenger RNAs that may or may not include exon 14 of BCR (e13a2 and e14a2, respectively), and, as a consequence, in two p210BCR-ABL1 proteins that differ by 25 amino acids, may be a cause of persistence. The hypothesis is based on a critical review of the relationships between the BCR-ABL1 transcript types, the response to TKIs, the outcome of treatment, and the immune response, suggesting that the e14a2 transcript is associated with more and deeper molecular responses, hence with a higher probability of achieving treatment-free remission (TFR). Investigating this putative cause of persistence may help bringing more patients into stable TFR.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Baccarani M, Rosti G, Soverini S, et al. Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type. Leukemia. 2019. PMID: 31455852. doi:10.1038/s41375-019-0562-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。